Literature DB >> 11733563

High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection.

J D Ahlers1, I M Belyakov, E K Thomas, J A Berzofsky.   

Abstract

Natural viral proteins do not always make optimal vaccines. We have found that sequence modification to increase epitope affinity for class II MHC molecules (epitope enhancement) can improve immunogenicity. Here we show first that a higher-affinity helper epitope-enhanced HIV vaccine not only induces more cytotoxic T lymphocytes (CTLs), but also skews helper cells toward Th1 cytokine production and protects against HIV-1 recombinant vaccinia viral challenge. Furthermore, we elucidate a novel mechanism in which the higher-affinity vaccine induces dramatically more effective helper cells with a higher level of CD40L per helper cell and more positive cells, which in turn more effectively conditions dendritic cells (DCs) for CTL activation in a second culture. The improved helper cells also induce much greater IL-12 production by DCs, accounting for the reciprocal T helper polarization to Th1, and increase costimulatory molecule expression. Thus, increasing affinity for class II MHC results in a complementary interaction in which T helper and antigen-presenting cells polarize each other, as well as increase CTL, and provide greater vaccine efficacy against viral infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11733563      PMCID: PMC200990          DOI: 10.1172/JCI13463

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity.

Authors:  R R Pogue; J Eron; J A Frelinger; M Matsui
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

2.  Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.

Authors:  M A Alexander-Miller; G R Leggatt; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

3.  Peptide analogs with different affinites for MHC alter the cytokine profile of T helper cells.

Authors:  P Chaturvedi; Q Yu; S Southwood; A Sette; B Singh
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

4.  IL-15 stimulates the expansion of AIDS virus-specific CTL.

Authors:  T Kanai; E K Thomas; Y Yasutomi; N L Letvin
Journal:  J Immunol       Date:  1996-10-15       Impact factor: 5.422

5.  Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells.

Authors:  S E Macatonia; N A Hosken; M Litton; P Vieira; C S Hsieh; J A Culpepper; M Wysocka; G Trinchieri; K M Murphy; A O'Garra
Journal:  J Immunol       Date:  1995-05-15       Impact factor: 5.422

6.  Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells.

Authors:  H Takahashi; Y Nakagawa; K Yokomuro; J A Berzofsky
Journal:  Int Immunol       Date:  1993-08       Impact factor: 4.823

7.  Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from alpha beta TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-gamma production is IFN-gamma-dependent.

Authors:  S E Macatonia; C S Hsieh; K M Murphy; A O'Garra
Journal:  Int Immunol       Date:  1993-09       Impact factor: 4.823

8.  Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

Authors:  M R Parkhurst; M L Salgaller; S Southwood; P F Robbins; A Sette; S A Rosenberg; Y Kawakami
Journal:  J Immunol       Date:  1996-09-15       Impact factor: 5.422

9.  Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.

Authors:  M Cella; D Scheidegger; K Palmer-Lehmann; P Lane; A Lanzavecchia; G Alber
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

10.  Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo.

Authors:  C Pfeiffer; J Stein; S Southwood; H Ketelaar; A Sette; K Bottomly
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

View more
  16 in total

1.  A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L.

Authors:  Jeffrey D Ahlers; Igor M Belyakov; Masaki Terabe; Rima Koka; Debra D Donaldson; Elaine K Thomas; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

Review 2.  Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; SangKon Oh; Igor M Belyakov; Jeffrey D Ahlers; John E Janik; John C Morris
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

3.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Authors:  Igor M Belyakov; Scott A Hammond; Jeffrey D Ahlers; Gregory M Glenn; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

4.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy.

Authors:  Rolf Billeskov; Yichuan Wang; Shahram Solaymani-Mohammadi; Blake Frey; Shweta Kulkarni; Peter Andersen; Else Marie Agger; Yongjun Sui; Jay A Berzofsky
Journal:  J Immunol       Date:  2017-03-27       Impact factor: 5.422

Review 6.  A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses.

Authors:  Jay A Berzofsky
Journal:  Vaccine       Date:  2011-11-21       Impact factor: 3.641

7.  Lack of IL-7 and IL-15 signaling affects interferon-γ production by, more than survival of, small intestinal intraepithelial memory CD8+ T cells.

Authors:  Dmitry Isakov; Amiran Dzutsev; Jay A Berzofsky; Igor M Belyakov
Journal:  Eur J Immunol       Date:  2011-12       Impact factor: 5.532

Review 8.  Progress on new vaccine strategies against chronic viral infections.

Authors:  Jay A Berzofsky; Jeffrey D Ahlers; John Janik; John Morris; SangKon Oh; Masaki Terabe; Igor M Belyakov
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

9.  Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.

Authors:  James T Snyder; Igor M Belyakov; Amiran Dzutsev; François Lemonnier; Jay A Berzofsky
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Antigen signal strength during priming determines effector CD4 T cell function and antigen sensitivity during influenza virus challenge.

Authors:  Mika Nagaoka; Yasuko Hatta; Yoshihiro Kawaoka; Laurent P Malherbe
Journal:  J Immunol       Date:  2014-08-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.